Product review: avelumab, an anti-PD-L1 antibody.

38 , 69 , 72 , 73 However, an exploratory post-hoc analysis of 29 samples from JAVELIN Solid Tumor did not reach statistical significance ( p = 0.076, Wilcoxon rank sum test), possibly due to small sample size. 67 Assessment of antitumor response associated with mutational burden and PD-L1 expression as a combined measure could provide further insights into the possible predictive role of these biomarkers.

also in 111,027 other papers

78 - 80 Preliminary analysis of NSCLC patients from the JAVELIN Solid Tumor trial showed a trend toward higher ORR with increasing avelumab trough concentrations and higher levels of PD-L1 expression.

also in 53,322 other papers